Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria 125 39 39 5 5 The Microalbuminuria Captopril Study Group Summary In insulin-dependent diabetes mellitus (IDDM), microalbuminuria predicts renal and cardiovascular disease. We report a combined analysis of 235 normotensive IDDM patients with microalbuminuria who participated in two 24-month double-blind, randomised, placebo-controlled trials to assess the effects of captopril 50 mg twice daily on the progression to overt clinical albuminuria. Of the 225 patients who were evaluable on an intent to treat basis, 25 of 114 placebo-treated patients (21.9%) and 8 of 111 captopril-treated patients (7.2%) progressed to persistent clinical albuminuria. The risk of progression over 24 months was significantly reduced by captopril ( p =0.004) with a risk reduction of 69.2% (95% confidence interval (CI): 31.7 to 86.1%). This degree of risk reduction remained at the same level (62.9% (16.1–83.6%), p =0.017) after adjustment for differences in time-varying mean arterial blood pressure. Albumin excretion rate increased by an average of 14.2% (3.1–26.5%) per year in the placebo-treated group compared with a reduction of 9.6% (−18.6–0.4%) per year in the captopril-treated group ( p =0.002). The rate of fall of creatinine clearance tended to be faster in the placebo-treated group than in the captopril-treated group (−6.4 (−10.2–−2.5) vs −1.4 (−5.3–2.6) ml · min −1 · 1.73 m −2 , p =0.07). Baseline albumin excretion rate ( p <0.0001) and glycated haemoglobin ( p =0.03) were independent predictors of progression to clinical albuminuria and changes in mean arterial blood pressure ( p =0.02) and serum cholesterol level ( p =0.003) were significantly associated with percentage changes in albumin excretion rate. Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

Diabetologia, Volume 39 (5) – May 1, 1996

Loading next page...
 
/lp/springer-journals/captopril-reduces-the-risk-of-nephropathy-in-iddm-patients-with-t6y1085tWN
Publisher
Springer Journals
Copyright
Copyright © 1996 by Springer-Verlag
Subject
Medicine & Public Health; Human Physiology; Internal Medicine; Metabolic Diseases
ISSN
0012-186X
eISSN
1432-0428
DOI
10.1007/BF00403306
Publisher site
See Article on Publisher Site

Abstract

125 39 39 5 5 The Microalbuminuria Captopril Study Group Summary In insulin-dependent diabetes mellitus (IDDM), microalbuminuria predicts renal and cardiovascular disease. We report a combined analysis of 235 normotensive IDDM patients with microalbuminuria who participated in two 24-month double-blind, randomised, placebo-controlled trials to assess the effects of captopril 50 mg twice daily on the progression to overt clinical albuminuria. Of the 225 patients who were evaluable on an intent to treat basis, 25 of 114 placebo-treated patients (21.9%) and 8 of 111 captopril-treated patients (7.2%) progressed to persistent clinical albuminuria. The risk of progression over 24 months was significantly reduced by captopril ( p =0.004) with a risk reduction of 69.2% (95% confidence interval (CI): 31.7 to 86.1%). This degree of risk reduction remained at the same level (62.9% (16.1–83.6%), p =0.017) after adjustment for differences in time-varying mean arterial blood pressure. Albumin excretion rate increased by an average of 14.2% (3.1–26.5%) per year in the placebo-treated group compared with a reduction of 9.6% (−18.6–0.4%) per year in the captopril-treated group ( p =0.002). The rate of fall of creatinine clearance tended to be faster in the placebo-treated group than in the captopril-treated group (−6.4 (−10.2–−2.5) vs −1.4 (−5.3–2.6) ml · min −1 · 1.73 m −2 , p =0.07). Baseline albumin excretion rate ( p <0.0001) and glycated haemoglobin ( p =0.03) were independent predictors of progression to clinical albuminuria and changes in mean arterial blood pressure ( p =0.02) and serum cholesterol level ( p =0.003) were significantly associated with percentage changes in albumin excretion rate. Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects.

Journal

DiabetologiaSpringer Journals

Published: May 1, 1996

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off